考點總覽

依 Fitzpatrick Part 瀏覽

• Part 1 Foundations of Clinical Dermatology17 個考點
• Part 2 Structure and Function of Skin124 個考點
• Part 3 Dermatitis118 個考點
• Part 4 Psoriasiform Disorders57 個考點
• Part 5 Lichenoid and Granulomatous Disorders48 個考點
• Part 6 Neutrophilic, Eosinophilic, and Mast Cell Disorders112 個考點
• Part 7 Reactive Erythemas75 個考點
• Part 8 Disorders of Cornification53 個考點
• Part 9 Vesiculobullous Disorders69 個考點
• Part 10 Autoimmune Connective Tissue and Rheumatologic Disorders80 個考點
• Part 11 Dermal Connective Tissue Disorders12 個考點
• Part 12 Subcutaneous Tissue Disorders15 個考點
• Part 13 Melanocytic Disorders53 個考點
• Part 14 Acneiform Disorders47 個考點
• Part 15 Disorders of Eccrine and Apocrine Sweat Glands30 個考點
• Part 16 Disorders of the Hair and Nails53 個考點
• Part 17 Disorders Due to the Environment53 個考點
• Part 18 Psychosocial Skin Disease21 個考點
• Part 19 Skin Changes across the Span of Life79 個考點
• Part 20 Neoplasia189 個考點
• Part 21 Metabolic, Genetic, and Systemic Diseases176 個考點
• Part 22 Vascular Diseases95 個考點
• Part 23 Bacterial Diseases55 個考點
• Part 24 Fungal Diseases42 個考點
• Part 25 Viral Diseases58 個考點
• Part 26 Sexually Transmitted Diseases44 個考點
• Part 27 Infestations, Bites, and Stings43 個考點
• Part 28 Topical and Systemic Treatments143 個考點
• Part 29 Physical Treatments31 個考點
• Part 30 Dermatologic Surgery89 個考點
• Part 31 Cosmetic Dermatology86 個考點

最常考的考點

考過 3 題以上的 150 個考點，依題數排序；點選後到所屬 Part 的考點頁看完整考法。

1. 藥物光毒性／光過敏幾乎都由 UVA 引起（芳香族藥物吸收 UVA）UVA in drug-induced photosensitivity8 題Ch.17
2. Carbamazepine SJS/TEN 與 HLA-B*15:02（漢人、東南亞；日韓歐洲不成立；非必要條件）Carbamazepine SJS/TEN and HLA-B*15:026 題Ch.44
3. PG 胎兒風險（small-for-gestational-age、早產）Pemphigoid gestationis: fetal risk6 題Ch.105
4. UV 紅斑 action spectrum 高峰 300 nm（UVB）；UVB 致紅性約 UVA 1000 倍Erythema action spectrum (UVB 1000x UVA)5 題Ch.17
5. 急性 AD 以 Th2 細胞激素 IL-4、IL-13 為代表Acute AD Th2 cytokines (IL-4, IL-13)5 題Ch.22
6. EM 多與感染相關，藥物不是常見病因EM etiology: mostly infection, rarely drugs5 題Ch.43
7. Netherton syndrome 經皮吸收增加（外用 tacrolimus 可達全身毒性濃度、TCI 列為禁忌）Netherton syndrome: increased percutaneous absorption and topical tacrolimus/TCI risk5 題Ch.47
8. Darier disease 致病基因（ATP2A2／SERCA2 鈣幫浦）Darier disease gene5 題Ch.50
9. PF 自體抗原（Dsg1）Pemphigus foliaceus autoantigen5 題Ch.52
10. PNP 自體抗原（desmoplakin I/II、envoplakin、periplakin）Paraneoplastic pemphigus autoantigens5 題Ch.53
11. PNP 頑固性口腔炎：最早、最恆定、最抗治療；無口腔炎不列入鑑別PNP intractable stomatitis5 題Ch.53
12. Vitiligo 合併自體免疫疾病（T1DM、autoimmune thyroiditis、pernicious anemia、Addison、SLE、alopecia areata；generalized 較多）Vitiligo autoimmune associations5 題Ch.76
13. HS 典型分布（腋下最常見、鼠蹊、臀、會陰、乳房下）Hidradenitis suppurativa distribution5 題Ch.84
14. HS 主要致病事件為 terminal hair follicle 角化阻塞（汗腺為續發受累）HS pathogenesis: follicular occlusion (sweat glands secondary)5 題Ch.84
15. NCCN 部位分區與大小切點（Area H 不論大小；Area M ≥10 mm；Area L ≥20 mm）NCCN cSCC location/size risk areas (H/M/L)5 題Ch.112
16. EMPD CK7／CK20 型態（primary 多 CK7+/CK20−；secondary 常 CK7+/CK20+）CK7/CK20 pattern in primary vs secondary EMPD5 題Ch.114
17. Nail matrix 切片變形風險（punch ≤3 mm；越近端風險越高）Nail matrix biopsy and dystrophy risk5 題Ch.205
18. 刺青顏色與雷射（黑：1064/755/694；紅／黃：532；藍綠：755/694；紫橘：532/755）Laser selection by tattoo ink color5 題Ch.210
19. 未經評讀的專家意見為最低證據等級Expert opinion as lowest level of evidence4 題Ch.3
20. RCT 以隨機分派與盲性降低 bias，為療效評估的 gold standard／最高層級單一研究RCT as highest-level single study design4 題Ch.3
21. FLG null mutations 為 atopic dermatitis（及合併 AD 的 asthma）易感因子Atopic dermatitis: FLG susceptibility4 題Ch.14
22. Immediate pigment darkening 主要 UVA（20 分鐘內）；delayed tanning 主要 UVB（約 3 天）Tanning: IPD (UVA) vs delayed tanning (UVB)4 題Ch.17
23. Oil spot／salmon patch 幾乎為乾癬特有Oil spot specificity for psoriasis4 題Ch.28
24. 誘發 lichenoid drug eruption 的藥物（Table 32-2）Lichenoid drug eruption culprit drugs4 題Ch.32
25. GA 與糖尿病的關聯（主要 type 1、較常見於 generalized／perforating GA；多數 GA 無糖尿病）Granuloma annulare and diabetes mellitus association4 題Ch.34
26. SPD 對稱分布於腋下、鼠蹊、乳房下、腹部與四肢屈側SPD distribution4 題Ch.38
27. SPD 頭皮與黏膜總是不受侵犯SPD spares scalp and mucosa4 題Ch.38
28. SPD 治療（dapsone 首選；類固醇）SPD treatment4 題Ch.38
29. EN 藥物風險分級（Table 44-3：高風險 allopurinol、sulfonamide、oxicam 等；diclofenac 中度；sulfonylurea、aspirin 非高風險）Epidermal necrolysis drug risk categories4 題Ch.44
30. AGEP 常見藥物（β-lactam、macrolide、quinolone、抗癲癇藥、diltiazem、terbinafine）AGEP culprit drugs4 題Ch.45
31. AGEP 特徵（急性發燒、neutrophilia、廣泛非毛囊性膿疱、用藥 24–48 小時內；無淋巴結腫大、無關節炎）AGEP features (incl. systemic features)4 題Ch.45
32. Darier disease 肢端與掌蹠表現（手背 AKV 樣丘疹、palmar pits／keratotic papules、PPK；hemorrhagic macules 最少見）Darier disease acral and palmoplantar features4 題Ch.50
33. Darier disease 指甲（nail fragility、疼痛縱裂、紅白縱紋、V-shaped nicks）Darier disease nail changes4 題Ch.50
34. PNP 相關腫瘤（NHL、CLL、Castleman、thymoma）PNP associated neoplasms4 題Ch.53
35. DH 首選 dapsone，數小時至數天見效，可作 therapeutic diagnosisDapsone for DH (rapid response)4 題Ch.59
36. Dactylitis 與 enthesitis、nail–entheseal complexDactylitis, enthesitis and nail–entheseal complex4 題Ch.65
37. PsA 眼部侵犯（conjunctivitis、uveitis 等）Ocular involvement in psoriatic arthritis4 題Ch.65
38. Vitiligo 致病機轉（CD8+ T cells→IFN-γ→keratinocyte CXCL10→招募 T cells）Vitiligo pathogenesis: CD8+ T cell–IFN-γ–CXCL10 axis4 題Ch.76
39. Vitiligo 病灶 leukotrichia／poliosis 代表毛囊儲備受損、治療反應差Leukotrichia and vitiligo prognosis4 題Ch.76
40. Acne fulminans 治療（先類固醇 2–4 週，再低劑量 isotretinoin 0.1 mg/kg/day 起始）Acne fulminans treatment4 題Ch.80
41. HS 與吸菸：危險因子、病情較重；戒菸改善症狀並減少術後新病灶HS and smoking4 題Ch.84
42. Actinic prurigo 兒童期（<10 歲）發病、多女性（亞洲人男多）、青春期改善Actinic prurigo onset and demographics4 題Ch.93
43. Erythema toxicum neonatorum 膿疱含大量 eosinophilsErythema toxicum neonatorum histopathology4 題Ch.103
44. AEP 無胎兒風險（母胎預後極佳）Atopic eruption of pregnancy: no fetal risk4 題Ch.105
45. ICP 胎兒風險（早產、產程胎兒窘迫、胎死；與膽酸濃度相關）Intrahepatic cholestasis of pregnancy: fetal risk4 題Ch.105
46. Impetigo herpetiformis 胎兒風險（胎盤功能不全→死產、新生兒死亡）Pustular psoriasis of pregnancy: fetal risk4 題Ch.105
47. Impetigo herpetiformis 好發第三孕期（最早可第一孕期），持續至生產Pustular psoriasis of pregnancy: trimester of onset4 題Ch.105
48. AK 進展為 invasive SCC 的比例（整體約 5–10%；單一病灶每年 <1%）AK progression rate to SCC4 題Ch.110
49. 免疫抑制（器官移植、CLL）為 SCC 高危險因子；心肺移植風險更高Immunosuppression as cSCC high-risk factor4 題Ch.112
50. 發生於疤痕、慢性潰瘍／發炎或放療部位的 SCC 為高危險（轉移率 18–40%）cSCC arising in scars, chronic inflammation, or prior RT sites4 題Ch.112
51. MCC 對放射線敏感：窄邊緣切除＋輔助放療；不適手術者可單用放療Radiosensitivity and adjuvant RT in MCC4 題Ch.113
52. GCDFP-15（apocrine 標記）primary EMPD 多陽性、secondary 多陰性GCDFP-15 in primary vs secondary EMPD4 題Ch.114
53. KMP 幾乎只見於 tufted angioma 與 KHE，不發生於 IHTumors associated with Kasabach-Merritt phenomenon4 題Ch.118
54. MF 早期好發非日曬部位（bathing trunk、皺摺處），可呈 poikilodermaMF predilection for sun-protected sites4 題Ch.119
55. Acute GVHD 為 Th1、chronic GVHD 以 Th2 為主，Th17 兩者皆參與Th polarization in acute vs chronic GVHD4 題Ch.129
56. 所有類型 KS（含 classic）皆有 HHV-8HHV-8 in all Kaposi sarcoma types4 題Ch.168
57. Lyme disease 致病菌 Borrelia burgdorferi（Ixodes tick 傳播）Lyme disease pathogen4 題Ch.179
58. Ustekinumab 標的（IL-12/23 p40）Ustekinumab mechanism4 題Ch.193
59. DFSP 主要治療為完整手術切除（Mohs／切緣確認的 staged excision）DFSP primary treatment: complete surgical excision4 題Ch.204
60. Pseudo-Darier sign（congenital smooth muscle hamartoma）Pseudo-Darier sign3 題Ch.1
61. DFSP 免疫染色（CD34+、Factor XIIIa−；dermatofibroma 相反）DFSP immunohistochemistry vs dermatofibroma3 題Ch.2
62. Eccrine 汗腺由交感節後 cholinergic 纖維支配，主要傳導物質為 acetylcholineEccrine gland innervation: sympathetic cholinergic3 題Ch.6
63. Filaggrin 在角質層中層降解為 NMF，維持屏障與保水Filaggrin degradation to NMF and barrier3 題Ch.14
64. Exfoliative toxin（exfoliatin A／B）造成 bullous impetigo 與 SSSS，切割 Dsg1Exfoliative toxins (ETA/ETB) cleave Dsg1 in bullous impetigo and SSSS3 題Ch.15
65. UVA 在光老化扮演核心角色（Table 17-2）Central role of UVA in photoaging3 題Ch.17
66. 光敏感反應經 photosensitized reaction 產生 singlet oxygen 等 ROSPhotosensitized reactions generate ROS3 題Ch.17
67. AD 屏障缺陷（cornified envelope 基因下降、ceramide 減少、蛋白酶上升、TEWL 增加）Skin barrier dysfunction in AD3 題Ch.22
68. 約 1/3 AD 有 filaggrin 缺乏表徵（IV、KP、hyperlinear palms）Clinical signs of filaggrin deficiency in AD3 題Ch.22
69. 慢性 AD IL-5 增加，促 eosinophil 發育與存活IL-5 in chronic AD3 題Ch.22
70. ACD 皮膚抗原呈現細胞（Langerhans cells、dermal DCs）Antigen-presenting cells in ACD3 題Ch.24
71. ACD 致敏期約 10–15 天且通常無症狀ACD sensitization phase3 題Ch.24
72. 致敏期淋巴結 naive T 分化為 memory／effector TT-cell differentiation in ACD sensitization3 題Ch.24
73. 染髮劑 PPD 過敏性接觸性皮膚炎（常見致敏原；頭皮腫脹結痂、眼瞼水腫）PPD hair-dye allergic contact dermatitis3 題Ch.24
74. Hapten 性質（<500 Da、親脂性）Hapten properties3 題Ch.24
75. Contact urticaria 診斷（open、prick、短時間 patch、specific IgE；備 anaphylaxis 急救）Testing for contact urticaria3 題Ch.27
76. Acitretin 懷孕禁忌（category X、停藥後 3 年）Acitretin in pregnancy3 題Ch.28
77. Cyclosporine 懷孕 category C、無致畸性Cyclosporine in pregnancy3 題Ch.28
78. MTX 懷孕禁忌（category X、致胎毒、墮胎）Methotrexate in pregnancy3 題Ch.28
79. Lupus pernio 代表慢性破壞性病程（留疤、鼻中膈穿孔、肺纖維化），預後差需積極治療Lupus pernio: chronic destructive course and poor prognosis3 題Ch.35
80. Sarcoidosis 胸部 X 光（hilar adenopathy 50–85%、>90% 異常）Chest radiograph in sarcoidosis3 題Ch.35
81. Sarcoidosis 皮膚病灶分 specific（有肉芽腫）與 nonspecific（EN，無肉芽腫）Specific vs nonspecific cutaneous sarcoidosis3 題Ch.35
82. Sweet syndrome 治療（系統性類固醇；KI、colchicine 為第一線）Sweet syndrome treatment3 題Ch.36
83. Pustular PG 幾乎只見於急性 IBD 惡化，控制 IBD 有助緩解Pustular PG and IBD3 題Ch.37
84. Vegetative PG 進展慢、多不合併系統疾病、預後佳Vegetative pyoderma gangrenosum3 題Ch.37
85. IgE 上升只見於 KD，ALHE 正常Serum IgE in Kimura disease vs ALHE3 題Ch.40
86. EPF 各型分布（classical 臉軀幹、20% 掌蹠；HIV 頭頸上軀幹近端四肢；infantile 頭皮）EPF distribution by subtype3 題Ch.40
87. EPF 第一線治療（外用類固醇、TCI、indomethacin）EPF first-line treatment3 題Ch.40
88. Cholinergic urticaria 約 2/3 對汗液抗原致敏（Malassezia globosa 的 MGL_1304）Cholinergic urticaria: sweat antigen MGL_13043 題Ch.41
89. Darier sign（mastocytosis，成人不一定明顯）Darier sign3 題Ch.42
90. 復發性 EM 治療（抗 HSV 預防；azathioprine、thalidomide、MMF）Recurrent EM treatment3 題Ch.43
91. EN：HLA-B*5801 與 allopurinolEpidermal necrolysis: HLA-B*5801 and allopurinol3 題Ch.44
92. SCORTEN 七項指標SCORTEN items3 題Ch.44
93. 藥物性痤瘡樣疹的藥物（lithium、isoniazid、glucocorticoids、高劑量 vitamin B 等）Drug-induced acneiform eruption culprits3 題Ch.45
94. Pseudoporphyria 的致病藥物（naproxen、NSAIDs、diuretics）Pseudoporphyria culprit drugs3 題Ch.45
95. Erythema migrans 為 Lyme disease（Borrelia）第一期皮疹Erythema migrans in Lyme disease3 題Ch.46
96. Ichthyosis vulgaris 由 FLG 功能喪失突變造成Ichthyosis vulgaris: FLG mutations3 題Ch.47
97. Netherton 毛幹異常（trichorrhexis invaginata／bamboo hair，IRS 角化異常、眉毛常見）Netherton syndrome: trichorrhexis invaginata3 題Ch.47
98. Netherton syndrome：SPINK5／LEKTI 缺乏致 KLK 過度活化、過度脫屑Netherton syndrome: SPINK5/LEKTI3 題Ch.47
99. Striate PPK 的致病基因（DSG1、DSP）Striate palmoplantar keratoderma genes3 題Ch.48
100. KP 發病年齡與年齡別分布（幼童臉／手臂；青少年成人四肢伸側；無 old-age 型）Keratosis pilaris onset age and age-specific distribution3 題Ch.49
101. Keratosis pilaris 好發部位（臉頰、上臂伸側、大腿、臀；會侵犯臉部）Keratosis pilaris distribution3 題Ch.49
102. Hailey-Hailey disease 致病基因（ATP2C1／SPCA1 鈣幫浦）Hailey-Hailey disease gene3 題Ch.50
103. 藥物性天疱瘡的主要藥物（thiol：penicillamine、captopril）Drug-induced pemphigus: culprit drugs3 題Ch.52
104. Rituximab 作用機轉（anti-CD20、B 細胞耗竭）Rituximab mechanism (anti-CD20)3 題Ch.52
105. PNP defining features（疼痛性口炎＋多形性皮疹）PNP defining features3 題Ch.53
106. PNP DIF：細胞間 IgG／C3 ± BMZ 沉積，偽陰性較 PV 常見、需重複切片PNP direct immunofluorescence3 題Ch.53
107. PNP 腫瘤切除後的病程（良性／包被性腫瘤完全切除可緩解；惡性腫瘤治療不影響）PNP course after tumor resection3 題Ch.53
108. 藥物性 BP 的誘發藥物（furosemide、ACE inhibitors、penicillins、etanercept、anti-PD-1、DPP4 inhibitors 等）Drug triggers of bullous pemphigoid3 題Ch.54
109. EBA 自體抗原（collagen VII）EBA autoantigen3 題Ch.56
110. IgA pemphigus 自體抗原（SPD 型 Dsc1；IEN 型 Dsg1／Dsg3）IgA pemphigus autoantigens3 題Ch.57
111. Morphea 無 acrosclerosis／sclerodactyly（與 SSc 區分）Absence of sclerodactyly in morphea3 題Ch.64
112. csDMARDs 對 enthesitis 與 axial PsA 無效，第一線為 TNF inhibitorcsDMARDs ineffective for axial PsA/enthesitis3 題Ch.65
113. Erythema nodosum 病因（鏈球菌、藥物如口服避孕藥、惡性腫瘤、TB）Erythema nodosum etiologies3 題Ch.73
114. Phenols（monobenzone、4-tert-butyl phenol）結構類似 tyrosine 而誘發脫色Phenol-induced vitiligo3 題Ch.76
115. Vitiligo 疾病活性徵象（Koebner、trichrome、confetti-like、inflammatory lesions）Vitiligo activity signs3 題Ch.76
116. Vitiligo 治療反應與部位（臉等有毛處佳；glabrous／acral 處差）Vitiligo response by body site3 題Ch.76
117. Wood lamp 於色素減少疾病鑑別（tinea versicolor 黃綠螢光；pityriasis alba 無螢光、不增強）Wood lamp in hypopigmentation differential3 題Ch.76
118. Nevus of Ota 治療首選 QS lasers（ruby、alexandrite、Nd:YAG）Nevus of Ota: Q-switched laser3 題Ch.77
119. 口服 retinoid（isotretinoin 等）致畸與避孕：育齡女性需避孕；不影響男性精子，男性不需避孕或停藥Systemic retinoid teratogenicity and contraception (no effect on male fertility)3 題Ch.78
120. Isotretinoin 併用 tetracyclines 增加 pseudotumor cerebri 風險Isotretinoin + tetracycline: pseudotumor cerebri3 題Ch.78
121. Rosacea 一般處置（避開誘發因子、防曬、皮膚照護）適用所有亞型Rosacea general measures for all subtypes3 題Ch.79
122. Rosacea 口服 isotretinoin（低劑量，phymata、Morbihan）Isotretinoin for rosacea3 題Ch.79
123. Rosacea 誘發因子（日曬、熱、冷、風、運動、辛辣、酒精、壓力）Rosacea triggers3 題Ch.79
124. 多汗症第一線外用 aluminum chloride hexahydrate 10%–35%（睡前塗於乾燥皮膚、6–8 小時後洗掉）Aluminum chloride hexahydrate as first-line topical therapy3 題Ch.81
125. HS 長期病灶併發 SCC（約 4.6%、少見、局部侵犯性強、淋巴轉移率高）SCC complicating HS3 題Ch.84
126. HS 生物製劑（adalimumab FDA 核准 first-line；infliximab 用於 adalimumab 無效者）TNF inhibitors for HS (adalimumab, infliximab)3 題Ch.84
127. 藥物性 TE（Table 86-2：vitamin A／retinoids、oral contraceptives 等）Drug-induced TE3 題Ch.86
128. TE 機轉：anagen 提早結束轉入 telogen（毛髮大小正常、無 miniaturization）TE mechanism: premature anagen termination3 題Ch.86
129. TE 為非疤痕性、可逆／自限的落髮Telogen effluvium: nonscarring, reversible3 題Ch.86
130. 杵狀指病因（Table 91-8：肺、心血管含 aortic aneurysm、先天心臟病、methemoglobinemia 等）Causes of digital clubbing3 題Ch.91
131. 外源性光敏感分 phototoxicity 與 photoallergyExogenous photosensitivity: phototoxicity vs photoallergy3 題Ch.97
132. Frostbite 治療為快速回溫（37–39°C 水浴）；慢回溫使冰晶變大Frostbite: rapid rewarming3 題Ch.98
133. Opiates 直接使 mast cell 釋放 histamine（urticaria、angioedema、heroin high pruritus）Opiate histamine release: urticaria and pruritus3 題Ch.101
134. 菸草與尼古丁（含電子煙）收縮血管、妨礙傷口癒合；建議術前術後各至少停用 1 週Tobacco/nicotine impairs wound healing3 題Ch.101
135. Aplasia cutis congenita 可為 NTD forme fruste、可能顱內連通，切片／刮取前須影像Aplasia cutis congenita and cranial dysraphism3 題Ch.103
136. 中線（鼻部）dermoid cyst 可顱內延伸（最多 25%），切片前應 MRIMidline dermoid cyst: intracranial extension3 題Ch.103
137. ETN 2–3 週自行消退、不留痕跡ETN course3 題Ch.103
138. ETN 見於最多 75% 足月兒、早產兒罕見ETN: term vs preterm infants3 題Ch.103
139. Impetigo herpetiformis 產後症狀迅速緩解（cardinal feature）Pustular psoriasis of pregnancy: postpartum resolution3 題Ch.105
140. Impetigo herpetiformis 後續懷孕常復發、更早更重Pustular psoriasis of pregnancy: recurrence3 題Ch.105
141. Impetigo herpetiformis 治療（系統性類固醇為過去主力；9e：cyclosporine、infliximab 一線）Pustular psoriasis of pregnancy: treatment3 題Ch.105
142. PEP 無胎兒風險Polymorphic eruption of pregnancy: no fetal risk3 題Ch.105
143. 慢性砷暴露皮膚癌常多發（arsenical keratoses、Bowen disease、superficial BCC、SCC）Arsenic-associated skin cancers3 題Ch.110
144. >60% 皮膚 SCC 源自既有 AKProportion of SCC arising from AK3 題Ch.110
145. NCCN 分化程度：poorly differentiated 為高危險；well／moderately 為低危險NCCN differentiation risk in cSCC3 題Ch.112
146. MCC 免疫染色（CK20+ perinuclear dot、TTF-1−、S-100−、LCA−；10–20% CK20 陰性）MCC immunohistochemistry3 題Ch.113
147. 血清 CEA 上升的 EMPD 死亡風險高，CEA 與病程平行、可用於追蹤Serum CEA in EMPD prognosis and surveillance3 題Ch.114
148. MUC2 primary EMPD 陰性，伴大腸直腸腺癌的 secondary EMPD 可陽性MUC2 in EMPD3 題Ch.114
149. BRAF 突變分布（SSM／NM、間歇日曬皮膚最高；acral、mucosal 低）BRAF mutation frequency by melanoma subtype3 題Ch.116
150. 原發 melanoma 不建議常規 CT／MRI／PET（偽陽性 8–15%）；Breslow ≥4 mm 或已知轉移才考慮Imaging workup in primary melanoma3 題Ch.116